Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MORRIS PLANS, N.J., March 05, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that Michael Pehl, President and Chief Executive Officer,...
-
MORRIS PLAINS, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that Michael Pehl, President and Chief Executive Officer,...
-
Presented Compelling Results with Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer (mTNBC) at San Antonio Breast Cancer Symposium Secured $250 Million Funding to Support Company’s...
-
MORRIS PLAINS, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that it will host a conference call on Thursday, February 8,...
-
Immunomedics to Fund Phase 2 Study Sponsored by the University of Wisconsin to Enable Further Investigation of Sacituzumab Govitecan in the Treatment of Patients with Castration-Resistant Prostate...
-
Royalty Pharma acquires Royalty Rights on Global Net Sales of Sacituzumab Govitecan (IMMU-132) Across All Indications for $175 Million Royalty Pharma Acquires $75 Million of Immunomedics Common Stock...
-
MORRIS PLAINS, N.J., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that Michael Pehl, President and Chief Executive Officer,...
-
Objective Response Rate (ORR) = 31% (Centrally Reviewed); 34% (Locally Assessed) Median Duration of Response (DOR) = 9.1 Months (Centrally Reviewed); 7.6 Months (Locally Assessed) Clinical Benefit...
-
MORRIS PLAINS, N.J., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that two of its abstracts were posted online at...
-
Announces Appointments of Michael Pehl as President and Chief Executive Officer and Brendan Delaney as Chief Commercial Officer Late-breaker Abstract on Updated Phase 2 Results of IMMU-132 in...